As of Friday close, BioCryst Pharmaceuticals Inc.’s (NASDAQ:BCRX) stock was down -$0.07, moving down -0.86 percent to $8.10. The average number of shares traded per day over the past five days has been 3,539,420 shares. 3 times new highs have been achieved over the past 5 days, with a -$0.19 fall in that time frame. In the last twenty days, the average volume was 3,965,230, while in the previous 50 days, it was 3,169,452.
Since last month, BCRX stock retreated -20.28%. Shares of the company fell to $7.82 on 03/10/23, the lowest level in the past month. A 52-week high of $18.00 was reached on 01/06/23 after having rallying from a 52-week low of $7.61. Since the beginning of this year, BCRX’s stock price has dropped by -29.44% or -$3.38, and marked a new high 3 times. However, the stock has declined by -55.00% since its 52-week high.
From Robots to Self-Driving Cars: 5 AI Stocks to Consider for Your Portfolio
The artificial intelligence (AI) revolution is already here and it's about to change everything we know about everything. With the global market for AI projected to grow from $137 billion in 2022 to over $1.81 trillion by 2030, there's never been a better time to invest in this burgeoning industry. That's why we've compiled a list of the Top 5 AI Stocks to Buy for 2023. These companies are at the forefront of the AI revolution, and have the potential to deliver huge returns to investors like you.
Get our free report, "Top 5 AI Stocks to Buy for 2023".
BCRX stock investors should be aware that BioCryst Pharmaceuticals Inc. (BCRX) stock had its last reported insider trading activity 45 days ago on Feb 01. Stonehouse Jon P, the President & CEO of the company, disposed of 100,000 shares for $10.38 on Feb 01. It resulted in a $1,038,000 divestment by the insider. Stonehouse Jon P sold 14,100 shares at an average price of $10.90 on Dec 15. The insider now owns 887,730 shares following the transaction. On Dec 15, Chief Commercial Officer Gayer Charles K sold 6,100 shares at $10.90 apiece. The transaction was valued at $66,490.
In the three months ended December 30, BioCryst Pharmaceuticals Inc.’s quick ratio stood at 4.60, while its current ratio was 4.90, showing that the company is able to pay off its debt. On the profitability front, the trailing twelve-month gross margin is 97.60% percent. In the year ended December 30, operating margins totaled -54.90%. Based on annual data, BCRX earned $264.42 million in gross profit and brought in $270.83 million in revenue.
A company’s management is another factor that investors consider when determining the profitability of an investment. In the past year, return on investment (ROI) was -34.50%. Return on equity (ROE) for the past 12 months was 108.10%.
In BioCryst Pharmaceuticals Inc.’s quarter-end financial report for December 30, it reported total debt of $231.62 million against cash and short-term investments of $119.54 million. According to the earnings report, the company had a higher net income in the recent quarter than it did in the previous quarter. BCRX’s revenue rose 40.72% to $75.83 million during the quarter, while net income inched up to $79.55 million. While analysts expected BioCryst Pharmaceuticals Inc. to report -$0.17 quarterly earnings, the actual figure was -$0.38 per share, beating the consensus estimate by -123.50%. During the quarter, the company generated -$46.87 million in EBITDA. The liabilities of BioCryst Pharmaceuticals Inc. were 844.6 million at the end of its most recent quarter ended December 30, and its total debt was $741.45 million. The value of shareholders’ equity is $188.45 million.
This quick technical analysis looks at BioCryst Pharmaceuticals Inc.’s (BCRX) price momentum. With a historical volatility rate of 23.93%, the RSI 9-day stood at 26.27% on 17 March.
With respect to its five-day moving average, the current BioCryst Pharmaceuticals Inc. price is down by -2.29% percent or -$0.19. At present, BCRX shares trade -18.35% below its 20-day simple moving average and -42.72% percent below its 100-day simple moving average. However, the stock is currently trading approximately -31.59% below its SMA50 and -13.00% below its SMA200.
Stochastic coefficient K was 27.67% and Stochastic coefficient D was 28.63%, while ATR was 0.37. Given the Stochastic reading of 21.21% for the 14-day period, the RSI (14) reading has been calculated as 30.47%. As of today, the MACD Oscillator reading stands at -0.12, while the 14-day reading stands at -0.30.